Effects of GABAB ligands alone and in combination with paroxetine on hippocampal BDNF gene expression

Leicester School of Pharmacy, Faculty of Health and Life Sciences, De Montfort University, The Gateway, Leicester, LE1 9BH, UK.
European journal of pharmacology (Impact Factor: 2.53). 09/2011; 671(1-3):33-8. DOI: 10.1016/j.ejphar.2011.09.001
Source: PubMed


Brain-derived neurotrophic factor (BDNF) has been suggested as a target for antidepressant treatment and chronic antidepressant drug administration shows a 'biphasic effect' on BDNF mRNA in rat hippocampus (transient decrease followed by an increase). In comparison, following acute administration only, an inhibitory action on BDNF gene expression is detected. The present study aimed to understand the mechanism behind the acute inhibitory action on BDNF gene expression by investigating the possible involvement of γ-aminobutyric acid (GABA) receptors in mediating this effect. Rats were injected with either saline, the GABA(A) selective compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP), the benzodiazepine flunitrazepam or the GABA(B) selective compound baclofen. BDNF mRNA levels were measured 4h later using in-situ hybridization. Baclofen (10mg/kg, i.p.), but not THIP (10mg/kg, i.p.) or flunitrazepam (10mg/kg, i.p.), administration resulted in significant inhibition of BDNF mRNA expression in the cornu ammonis 3 and dentate gyrus but not in the cornu ammonis 1 region of the hippocampus. The inhibitory effect of baclofen on hippocampal BDNF mRNA expression was significantly attenuated by pre-treatment the selective GABA(B) antagonists, CGP 46381 and CGP 55845 (10mg/kg, i.p.). The inhibitory action by the selective serotonin re-uptake inhibitor (SSRI) paroxetine on hippocampal BDNF mRNA was also attenuated by CGP 46381. Our findings suggest a role for GABA(B), but not GABA(A), receptor-mediated mechanisms in the inhibitory regulation of basal hippocampal BDNF gene expression. Our results indicate that GABA(B) receptor activation may play a role in the antidepressant drug-induced inhibition of BDNF gene expression in the hippocampus.

Download full-text


Available from: Ahmad Khundakar, Jun 30, 2015
    • "One of the mechanisms involved in neuroprotection mediated by GABA-B receptor is activity on BDNF expression and secretion. It was shown that the GABA-B receptor agonist baclofen (10 mg/kg, i.p.) significantly inhibited BDNF mRNA levels at 4 h after injection in the dentate gyrus and cornu ammonis 3 regions of the hippocampus , and the inhibitory effect of baclofen on BDNF mRNA was attenuated by the pre-treatment with the selective GABA-B antagonists[32]. In earlier study it was shown that BDNF expression is increased by almost 200% by addition of 100 M baclofen in cultured hippocampal neurons[33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: R-phenibut is a γ-aminobutyric acid (GABA)-B receptor and α2-δ subunit of the voltage-dependent calcium channel (VDCC) ligand. The aim of the present study was to test the effects of R-phenibut on the motor, sensory and tactile functions and histological outcomes in rats following transient middle cerebral artery occlusion (MCAO). In this study, MCAO was induced by filament insertion (f-MCAO) or endothelin-1 (ET1) microinjection (ET1-MCAO) in Male Wistar or CD rats, respectively. R-phenibut was administrated at doses of 10 and 50mg/kg for 14 days in the f-MCAO or 7 days in the ET1-MCAO. The vibrissae-evoked forelimb-placing and limb-placing tests were used to assess sensorimotor, tactile and proprioceptive function. Quantitative real time-PCR was used to detect brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) gene expression in the damaged brain hemisphere.Both f-MCAO and ET1-MCAO resulted in statistically significant impairment of sensorimotor function and brain infarction. R-phenibut at a dose of 10mg/kg significantly improved histological outcome at day 7 in the ET1-MCAO. R-phenibut treatment at a dose of 50mg/kg significantly alleviated reduction of brain volume in damaged hemisphere in both f-MCAO and ET1-MCAO. In R-phenibut treated animals a trend of recovery of tactile and proprioceptive stimulation in the vibrissae-evoked forelimb-placing test was observed. After R-phenibut treatment at a dose of 50mg/kg statistically significant increase of BDNF and VEGF gene expression was found in damaged brain hemisphere. Taken together, obtained results provide evidence for the neuroprotective activity of R-phenibut in experimental models of stroke. These effects might be related to the modulatory effects of the drug on the GABA-B receptor and α2-δ subunit of VDCC.
    No preview · Article · Nov 2015 · Pharmacological Research
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neurotrophins are a group of polypeptides that specifically influence neuronal activity during development and adult life in the central and peripheral nervous system (PNS). In particular, Schwann cells (SC) in the PNS exert a neurotrophic role following up-regulation of several growth factors, including nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF). Also SC-like cells derived from adipose tissue (dASC), which have molecular and functional properties similar to SC, can produce and secrete NGF and BDNF. Interestingly, gamma-aminobutyric acid (GABA) and its receptors have been also suggested as modulators of development and myelination in PNS. Therefore, it was interesting to investigate whether the stimulation of the GABA-B receptor may regulate the expression of neurotrophins in SC and dASC. Our findings demonstrated that the specific GABA-B receptors agonist baclofen influences the expression and the secretion NGF and BDNF. In particular, 2 and 24 h of baclofen exposure lead to increased neurotrophins expression in both SC and dASC, as measured by western blot. Moreover, enzyme-linked immunosorbent assay showed that also the levels of released neurotrophins were modified after baclofen treatments. The possibility to modulate the neurotrophic potential of adult stem cell, acting on functional GABAergic receptors, could represent a novel pharmacological approach to improve nerve regeneration.
    No preview · Article · May 2012 · Journal of Molecular Neuroscience
  • [Show abstract] [Hide abstract]
    ABSTRACT: GABA(B) receptor antagonists have been shown to have antidepressant-like properties in animal models and thus, could represent a novel approach for the treatment of depression. The neurobiological mechanisms underlying these effects are currently unknown. Adult hippocampal neurogenesis (the birth of new neurons) is thought to play a role in antidepressant drug action. However, the ability of GABA(B) receptors to modulate the proliferation and survival of newly-born cells in the adult hippocampus remains unexplored. Therefore, we investigated whether the GABA(B) receptor antagonist, CGP 52432, can induce antidepressant-like behaviour and increase hippocampal neurogenesis in the stress-sensitive mouse strain, BALB/c. Male mice were treated with CGP 52432 either acutely (one injection, 3; 10; 30 mg/kg, i.p.), subchronically (7 days, 3; 10 mg/kg, i.p.) or chronically (21 days, 3; 10 mg/kg, i.p.) and antidepressant-like behaviour was assessed using the forced swim test (FST). The effects of CGP 52432 on the proliferation and survival of newly-born cells in the hippocampus were assessed using BrdU immunohistochemistry. Acute, subchronic and chronic treatment with CGP 52432 induced antidepressant-like behavioural effects in the FST. Moreover, chronic but not acute or subchronic treatment with CGP 52432 increased hippocampal cell proliferation but had no effect on the survival of newly-born cells. This temporal effect is consistent with the time course for the therapeutic action of antidepressants. Interestingly, CGP 52432-induced increases in cell proliferation occurred in the ventral but not in the dorsal hippocampus. This topographical segregation concurs with the hypothesis that the ventral hippocampus is primarily involved in the regulation of stress and emotionality. Taken together, our data suggest that increased hippocampal cell proliferation is a plausible mechanism for the antidepressant-like effects of GABA(B) receptor antagonists following chronic but not acute treatments. Moreover, altered behavioural effects in the FST does not correlate with changes in neurogenesis.
    No preview · Article · Aug 2012 · Neuropharmacology
Show more